Non Hodgkin's Lymphoma News and Research

RSS

The Non-Hodgkin lymphomas (NHLs) are a diverse group of hematologic cancers which encompass any lymphoma other than Hodgkin's Lymphoma.

Half of patients with aggressive non-Hodgkin's lymphoma fail to receive the recommended dose and schedule of chemotherapy

Approximately half of patients with aggressive non-Hodgkin's lymphoma (NHL) fail to receive the recommended dose and schedule of chemotherapy, reducing their chances for remission or cure.

20 Sep 2004

Health problems among timber workers exposed to industry chemical PCP are to be investigated

The project, funded by the Ministry of Health, aims to ascertain whether timber workers exposed to the PCPs (pentachlorophenols) are dying earlier, getting cancers more often and suffering more chronic health problems, including fatigue, nausea and neuropsychological dysfunction.

13 Sep 2004

Exposure to simian virus 40 (SV40) is not associated with cancer in humans

Two upcoming studies by scientists at the National Cancer Institute (NCI), provide further evidence that exposure to simian virus 40 (SV40) is not associated with cancer in humans.

23 Aug 2004

Cell Therapeutics receives Fast Track Designation for Pixantrone, treatment for aggressive non-Hodgkin's lymphoma

Cell Therapeutics, Inc. has received fast track designation from the U.S. Food and Drug Administration (FDA) for pixantrone, a novel anthracenedione, being investigated for the potential treatment of relapsed, aggressive non-Hodgkin's lymphoma (NHL).

12 Jul 2004

Omega-3's - fatty acids, can be produced in bioengineered plants

Long-chain omega-3 polyunsaturated fatty acids (n-3 LC-PUFAs) have benefits regarding cardiovascular and inflammatory function, certain types of cancer, and maternal and infant health, according to recent peer-reviewed studies.

2 Jul 2004

Results from study of Rituxan in rheumatoid arthritis show promise

Genentech, Inc., Biogen Idec and Roche have announced that the New England Journal of Medicine published the results of a Phase IIa study showing that two doses of Rituxan® (Rituximab), administered two weeks apart, improved symptoms in patients with moderate-to-severe rheumatoid arthritis (RA) for up to 48 weeks when combined with methotrexate (MTX), compared to MTX alone.

16 Jun 2004

Drug Tarceva improves survival chance for patients with advanced lung cancer

Roche OSI Pharmaceuticals and Genentech today announced that their investigational drug Tarceva(TM) (erlotinib) achieved a significant 42.5% improvement in median survival compared to placebo in patients with advanced non-small cell lung cancer (NSCLC).

5 Jun 2004

Cancer rates falling in the US

The nation's leading cancer organizations report that Americans' risk of getting and dying from cancer continues to decline and survival rates for many cancers continue to improve.

3 Jun 2004

Umbilical cord blood and bone marrow transplants slow the progression of many cancers

Umbilical cord blood and bone marrow transplants at Loyola University Health System, Maywood, Ill., are curing or slowing the progression of many cancers originating in the bone marrow (i.e., leukemia, myeloma) or lymphatic system (lymphoma).

3 Jun 2004

Higher rate of cancer in meat industry

A study of over 6600 meat industry workers around New Zealand has found a significantly high rate of cancers, particularly lung cancer, which may be caused by exposure to cancer causing agents carried by animals.

31 May 2004

Scientists identify six genes associated with the most common form of non-Hodgkin's lymphoma

In a paper that will be published on Thursday, April 29, 2004 in the New England Journal of Medicine, a team of scientists from Stanford University and Applied Biosystems, an Applera Corporation business, describe the identification of six genes associated with survival in diffuse large B cell lymphoma (DLBCL), the most common form of non-Hodgkin's lymphoma.

28 Apr 2004

Experimental immune-boosting drug interleukin-2 helps HIV Patients

National Institutes of Health (NIH) scientists report that brief, widely-spaced courses of the experimental immune-boosting drug interleukin-2 (IL-2) allow people with HIV to maintain near normal levels of a key immune system cell for long periods.

26 Apr 2004

Newly diagnosed non-Hodgkin’s lymphoma linked to monkey virus DNA

Examination of tumors in patients with newly diagnosed non-Hodgkin’s lymphoma found that half of them show evidence of a monkey virus DNA that may have originated from contaminated polio vaccines.

30 Mar 2004